Clover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Lags Revenue Estimates
Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
Clover Health Investments, Corp. (CLOV) Q3 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS John French - Leerink Partners Operator Ladies and gentlemen, good afternoon. And welcome to the Clover Health Third Quarter 2024 Earnings Conference Call.
Clover Health's Rally: The Payoff Of A Profitable Pivot
Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched Counterpart Health platform could diversify the company's revenue, offsetting risks from declining Medicare Advantage memberships. The company has a strong balance sheet with no long-term debt and high liquidity ratios.
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.
Chamath Palihapitiya Loves This Stock, But Is It a Buy?
Chamath Palihapitiya is a prominent venture capitalist, engineer, and entrepreneur known for his significant contributions to the tech sector.
Undercovered Dozen: Clover Health, Quipt, Vital Energy, STMicroelectronics +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks with strong potential, aiming to provide investment ideas and spark community discussion. Dmytro Konovalov takes a look at the impacts of TC Energy spin-off South Bow and sees stable revenues and growth potential in the Western Canadian Sedimentary Basin. Marvell Technology's turnaround is driven by growth in AI, data centers, and custom ASICs, presenting a compelling investment opportunity according to Simple Investing.
Clover Health Investments, Corp. (CLOV) Hits Fresh High: Is There Still Room to Run?
Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Chamath Palihapitiya Was Way Wrong About This Stock, But Was 100% Correct About the Industry
While special purpose acquisition companies (SPACs) have been around for years, they really burst onto the mainstream investor's consciousness in 2020.
Why Fast-paced Mover Clover Health Investments (CLOV) Is a Great Choice for Value Investors
Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Despite Fast-paced Momentum, Clover Health Investments (CLOV) Is Still a Bargain Stock
Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
CLOV Stock Alert: What to Know About Clover Health's Big Insider Buy
Clover Health (NASDAQ: CLOV ) co-founder and Executive Chairman Vivek Garipalli bought 531,700 shares of his troubled health insurance company this month. The executive now owns over 1.4 million shares.
Clover Health Investments, Corp. (CLOV) Hit a 52 Week High, Can the Run Continue?
Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
